It is recommended that adalimumab is usually administered by injection every two weeks or as directed by the doctor. Adalimumab is an anti-TNF-a monoclonal antibody, which is mainly used for the treatment of rheumatoid arthritis, ankylosing spondylitis and other rheumatic immune diseases. Adalimumab is generally recommended to be injected subcutaneously every two weeks. It can be used alone or in combination with other medications such as methotrexate. Adverse reactions such as redness and swelling at the injection site, infection, headache and musculoskeletal pain may occur with adalimumab. It is contraindicated in people who are allergic to the product or other ingredients in the preparation, in patients with active tuberculosis or other serious infectious diseases, and in patients with moderate to severe heart failure. Precautions: Before, during, and after the use of this product, patients must be closely monitored for the development of infections such as tuberculosis, and when a patient develops a new serious infection or reactivation of hepatitis B, treatment with this product should be interrupted until the infection is controlled. If you suffer from related diseases requiring the use of adalimumab, you need to go to the rheumatology and immunology department of the hospital, exclude the use of contraindications before use, and regular follow-up to adjust the use of medication.